ZyVersa Therapeutics Inc (ZVSA)
1.08
-0.05
(-4.42%)
USD |
NASDAQ |
Nov 15, 16:00
1.06
-0.02
(-1.85%)
After-Hours: 20:00
ZyVersa Therapeutics Research and Development Expense (TTM): 2.153M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.153M |
| March 31, 2024 | 2.665M |
| December 31, 2023 | 3.208M |
| September 30, 2023 | 4.238M |
| June 30, 2023 | 5.898M |
| Date | Value |
|---|---|
| March 31, 2023 | 5.397M |
| December 31, 2022 | 5.408M |
| September 30, 2022 | 4.754M |
| June 30, 2022 | 2.827M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.153M
Minimum
Jun 2024
5.898M
Maximum
Jun 2023
4.061M
Average
4.238M
Median
Sep 2023
Research and Development Expense (TTM) Benchmarks
| NeuroBo Pharmaceuticals Inc | 21.36M |
| Dermata Therapeutics Inc | 5.648M |
| Cognition Therapeutics Inc | 45.40M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |